1. Home
  2. TMQ vs BWAY Comparison

TMQ vs BWAY Comparison

Compare TMQ & BWAY Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Trilogy Metals Inc.

TMQ

Trilogy Metals Inc.

HOLD

Current Price

$2.36

Market Cap

579.8M

ML Signal

HOLD

Logo BrainsWay Ltd.

BWAY

BrainsWay Ltd.

SELL

Current Price

$11.41

Market Cap

547.7M

Sector

Health Care

ML Signal

SELL

Company Overview

Basic Information
Metric
TMQ
BWAY
Founded
2004
2003
Country
Canada
Israel
Employees
N/A
N/A
Industry
Precious Metals
Medical/Dental Instruments
Sector
Basic Materials
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
579.8M
547.7M
IPO Year
2012
2011

Fundamental Metrics

Financial Performance
Metric
TMQ
BWAY
Price
$2.36
$11.41
Analyst Decision
Buy
Strong Buy
Analyst Count
6
3
Target Price
$6.52
★ $19.27
AVG Volume (30 Days)
★ 1.1M
102.6K
Earning Date
10-02-2026
11-10-2026
Dividend Yield
N/A
N/A
EPS Growth
N/A
★ N/A
EPS
N/A
★ N/A
Revenue
N/A
N/A
Revenue This Year
N/A
$32.42
Revenue Next Year
N/A
$23.40
P/E Ratio
★ N/A
$81.98
Revenue Growth
N/A
N/A
52 Week Low
$2.30
$11.34
52 Week High
$7.25
$26.63

Technical Indicators

Market Signals
Indicator
TMQ
BWAY
Relative Strength Index (RSI) 18.75 33.15
Support Level N/A N/A
Resistance Level $3.99 $14.71
Average True Range (ATR) 0.12 0.49
MACD -0.06 -0.02
Stochastic Oscillator 6.11 3.20

Price Performance

Historical Comparison
TMQ
BWAY

About TMQ Trilogy Metals Inc.

Trilogy Metals Inc is an exploration stage company engaged in mineral exploration. The company focuses on exploring and developing its mineral resource properties, which include the Upper Kobuk Mineral Projects (UKMP or UKMP Projects), in the Ambler mining district located in Alaska, the USA. Its properties include the Arctic copper-zinc-gold-silver project and other mineralized targets within a volcanogenic massive sulfide belt, and it also has a bornite carbonate-hosted copper project.

About BWAY BrainsWay Ltd.

BrainsWay Ltd is engaged in advanced noninvasive neurostimulation treatments for mental health disorders. The company is advancing neuroscience with its proprietary Deep Transcranial Magnetic Stimulation (Deep TMS) platform technology to improve health and transform lives. Current indications include depressive disorder (including reduction of anxiety symptoms, commonly referred to as anxious depression), obsessive-compulsive disorder, and smoking addiction. Additional clinical trials of Deep TMS in various psychiatric, neurological, and addiction disorders are underway. The company derives revenues from the lease and sale of Deep TMS systems.

Share on Social Networks: